Katharine Hsu
Katharine Chia-Rae Hsu | |
|---|---|
| Alma mater | Stanford University (BS, MS) Cornell University (PhD, MD) |
| Known for | Director of Tri-Institutional MD–PhD Program since 2021 |
| Scientific career | |
| Fields | Hematology, oncology |
| Institutions |
|
| Thesis | Mechanisms of TNF receptor action: Studies using chimeric receptor mutants (1993) |
| Doctoral advisor | Moses Chao |
Katharine Chia-Rae Hsu[1] is an American physician-scientist in the field of research in human natural killer cells. Hsu has worked as an attending physician and member at Memorial Sloan Kettering Cancer Center.[2]
She has been a professor of medicine at Weill Cornell Medicine, and director of the Tri-Institutional MD–PhD Program.[3]
Education
Hsu received a Bachelor of Science and a Master of Science from Stanford University in 1987. She received a Doctor of Philosophy in cell biology in 1993 and a Doctor of Medicine in 1994, both from Cornell University.[3][4][5]
During her doctoral studies at Cornell University, she studied at the laboratory of Moses Chao.[3] Her doctoral dissertation was titled, Mechanisms of TNF receptor action: Studies using chimeric receptor mutants.[6]
Hsu completed an internship and residency in internal medicine at Brigham and Women's Hospital in Boston in 1997.[3] She completed a postdoctoral fellowship in hematology and oncology at Memorial Sloan Kettering Cancer Center in New York City in 2002.[3][7]
Career
Hsu joined the faculty of Memorial Sloan Kettering Cancer Center where she has worked as an attending physician and member in the Immuno-oncology Program.[2] She specializes in the treatment of blood cancers.[3] Her field of research is natural killer cells in humans and their role in killing cancer cells and cells with viruses.[2]
Hsu was inducted into the American Society for Clinical Investigation in 2012.[3] She is a member of the Association of American Physicians.[8]
She became a professor of medicine at Weill Cornell Medicine in 2017.[4] In April 2021, Hsu was named the director of the Tri-Institutional MD–PhD Program, succeeding Olaf Sparre Andersen.[3]
References
- ^ "Mechanisms of TNF receptor action: Studies using chimeric receptor mutants - ProQuest". www.proquest.com. Retrieved 2024-10-30.
- ^ a b c "The Katharine Hsu Lab". mskcc.org. Retrieved 2025-12-09.
- ^ a b c d e f g h "The Katharine Hsu Lab". news.weill.cornell.edu. Retrieved 2025-12-09.
- ^ a b "Hsu, Katharine". vivo.weill.cornell.edu. Retrieved 2024-10-30.
- ^ "Katharine C. Hsu, MD, PhD - MSK Bone Marrow Transplant Specialist". www.mskcc.org. Retrieved 2025-12-09.
- ^ Hsu, Katharine C. (1993). Mechanisms of TNF Receptor Action: Studies Using Chimeric Receptor Mutants (Ph.D. thesis). Cornell University. OCLC 39556864.
- ^ "Dr. Katharine Hsu, MD, PhD, Oncology | New York, NY | WebMD". doctor.webmd.com. Retrieved 2024-10-30.
- ^ "Association of American Physicians". aap-online.org. Retrieved 2025-12-18.